LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes

References

• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• O’DonnellDESciurbaFCelliBEffect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPDChest200613064765616963658
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J20042383284015218994
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther20102325726720381630
   PubMed Web of Science ®Google Scholar
• IkedaTAnisuzzamanASYoshikiHRegional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airwaysBr J Pharmacol201216661804181422300233
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLPageCPPharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEur J Pharmacol201474513514325446566
   PubMed Web of Science ®Google Scholar
• TashkinDPDonohueJFMahlerDAEffects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med200910351652419208459
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J2005621422216055868
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax20126778178822544891
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• SantusAssessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patientsRespir Physiol Neurobiol2014197364524726342
   PubMed Web of Science ®Google Scholar
• MartinJCarrizoSGasconMInspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20011631395139911371407
   PubMed Web of Science ®Google Scholar
• MatareseASantulliGAngiogenesis in chronic obstructive pulmonary disease: a translational appraisalTransl Med Uni Sa201234956
   Google Scholar
• WedzichaJDecramerMSeemungalTThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J2012401545155422835613
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med20143711285129425196117
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology2004945846515612956
   PubMed Web of Science ®Google Scholar
• TakahashiTIchinoseMInoueHUnderdiagnosis and undertreatment of COPD in primary care settingsRespirology2003850450814629656
   PubMed Web of Science ®Google Scholar
• OnishiKYoshimotoDHaganGWPrevalence of airflow limitation in outpatients with cardiovascular diseases in JapanInt J Chron Obstruct Pulmon Dis2014956356824920894
   PubMed Web of Science ®Google Scholar
• LandisSHMuellerovaHManninoDMContinuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013Int J Chron Obstruct Pulmon Dis2014959761124944511
   PubMed Web of Science ®Google Scholar
• IshikawaNHattoriNKohnoNAirway inflammation in Japanese COPD patients compared with smoking and nonsmoking controlsInt J Chron Obstruct Pulmon Dis201510118519225670894
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPMGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summaryAm J Respir Crit Care Med20011631256127611316667
   PubMedGoogle Scholar
• The Japanese Respiratory SocietyGuidelines for the Diagnosis and Treatment of COPD4th edTokyo, JapanJapanese Respiratory Society2013
   Google Scholar
• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summaryAm J Respir Crit Care Med201318734736522878278
   PubMed Web of Science ®Google Scholar
• PizzichiniEPizzichiniMMGibsonPSputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitisAm J Respir Crit Care Med19981585151115179817701
   PubMed Web of Science ®Google Scholar
• SuzukiMMakitaHItoYMClinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort studyEur Respir J20144351289129724232696
   PubMed Web of Science ®Google Scholar
• OhYMBhomeABBoonsawatWCharacteristics of stable chronic obstructive pulmonary disease patients in the pulmonology clinics of seven Asian citiesInt J Chron Obstruct Pulmon Dis20138313923378753
   PubMed Web of Science ®Google Scholar
• SeamanJLeonardACPanosRJHealth care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPDInt J Chron Obstruct Pulmon Dis20105899720463890
   PubMedGoogle Scholar
• FukuchiYNagaiASeyamaKet al; Research GroupTBClinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterolTreat Respir Med2005444745516336029
   PubMedGoogle Scholar
• SinDDMcAlisterFAManSFAnthonisenNRContemporary management of chronic obstructive pulmonary disease: scientific reviewJAMA2003290172301231214600189
   PubMed Web of Science ®Google Scholar
• BahadoriKFitzGeraldJMRisk factors of hospitalization and readmission of patients with COPD exacerbation: a systematic reviewInt J Chron Obstruct Pulmon Dis2007224125118229562
   PubMedGoogle Scholar
• Global initiative for chronic Obstructive Lung Disease (GOLD)2013 Available from: http://www.goldcopd.org/Guidelines/guideline-2013-gold-report.htmlAccessed May 14, 2015
   Google Scholar
• YusenRDEvolution of the GOLD documents for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Controversies and questionsAm J Respir Crit Care Med201318814523815714
   PubMed Web of Science ®Google Scholar
• PriceDBBakerCLZouKHReal-world characterization and differentiation of the global initiative for chronic obstructive lung disease strategy classificationInt J Chron Obstruct Pulmon Dis2014955156124920893
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med20131516024321804
   PubMed Web of Science ®Google Scholar
• RossiAGuerrieroMCorradoAWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res2014157725005873
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTOlmoRDINSTEAD: a randomized switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J2014441548155625359348
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• GershonASCampitelliMACroxfordRCombination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary diseaseJAMA20143121114112125226477
   PubMed Web of Science ®Google Scholar
• FinneyLBerryMSinganayagamAInhaled corticosteroids and pneumonia in chronic obstructive pulmonary diseaseLancet Respir Med2014291993225240963
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax2013681029103624130228
   PubMed Web of Science ®Google Scholar
• DiSantostefanoRLLiHHindsDRisk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysisInt J Chron Obstruct Pulmon Dis2014945746824855350
   PubMed Web of Science ®Google Scholar
• CalverleyPMTreating COPD in the real worldJAMA20143121101110225226474
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med20043502645265315215480
   PubMed Web of Science ®Google Scholar
• BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med201118466267121680942
   PubMed Web of Science ®Google Scholar
• BrightlingCEMonteiroWWardRSputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trialLancet20003561480148511081531
   PubMed Web of Science ®Google Scholar
• SivaRGreenRHBrightlingCEEosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trialEur Respir J20072990691317301099
   PubMed Web of Science ®Google Scholar
• SaettaMDi StefanoAMaestrelliPAirway eosinophilia in chronic bronchitis during exacerbationsAm J Respir Crit Care Med1994150164616527952628
   PubMed Web of Science ®Google Scholar
• BrightlingCEMcKennaSHargadonBSputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary diseaseThorax20056019319815741434
   PubMed Web of Science ®Google Scholar
• LeighRPizzichiniMMMorrisMMStable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEur Respir J20062796497116446316
   PubMed Web of Science ®Google Scholar
• KitaguchiYKomatsuYFujimotoKSputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthmaInt J Chron Obstruct Pulmon Dis2012728328922589579
   PubMed Web of Science ®Google Scholar
• HospersJJSchoutenJPWeissSTRijckenBPostmaDSAsthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sampleAm J Respir Crit Care Med19991601869187410588599
   PubMed Web of Science ®Google Scholar
• BafadhelMMcKennaSTerrySBlood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trialAm J Respir Crit Care Med2012186485522447964
   PubMed Web of Science ®Google Scholar
• BafadhelMDaviesLCalverleyPMBlood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysisEur Respir J20144478979124925917
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• NiewoehnerDEErblandMLDeupreeRHEffect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study GroupN Engl J Med19993401941194710379017
   PubMed Web of Science ®Google Scholar
• WagenerAHde NijsSBLutterRExternal validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthmaThorax201570211512025422384
   PubMed Web of Science ®Google Scholar
• HizawaNPharmacogenetics of chronic obstructive pulmonary diseasePharmacogenomics201314101215122523859575
   PubMed Web of Science ®Google Scholar
• SantulliGLombardiASorrientoDAge-related impairment in insulin release: the essential role of β(2)-adrenergic receptorDiabetes201261369270122315324
   PubMed Web of Science ®Google Scholar
• SantulliGIaccarinoGPinpointing beta adrenergic receptor in ageing pathophysiology: victim or executioner? Evidence from crime scenesImmun Ageing20131011023497413
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med20113641093110321428765
   PubMed Web of Science ®Google Scholar
• RabeKFFabbriLMIsraelEEffect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trialLancet Respir Med20141445324461901
   PubMed Web of Science ®Google Scholar
• GreenSATurkiJBejaranoPHallIPLiggettSBInfluence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cellsAm J Respir Cell Mol Biol19951325337598936
   PubMed Web of Science ®Google Scholar
• ChowdhuryBADal PanGThe FDA and safe use of long-acting β-agonists in the treatment of asthmaN Engl J Med2010362131169117120181964
   PubMed Web of Science ®Google Scholar
• CheungDTimmersMCZwindermanAHLong-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthmaN Engl J Med199232717119812031357550
   PubMed Web of Science ®Google Scholar
• McGrawDWAlmoosaKFPaulRJAntithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradoxJ Clin Invest200311261962612925702
   PubMed Web of Science ®Google Scholar
• WechslerMEKunselmanSJChinchilliVMEffect of β2- adrenergic receptor polymorphism on response to long-acting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trialLancet200937497031754176419932356
   PubMed Web of Science ®Google Scholar
• PistolesiMCamiciottoliGPaolettiMIdentification of a predominant COPD phenotype in clinical practiceRespir Med2008102367.e7618248806
   PubMed Web of Science ®Google Scholar
• BarnesPJGlucocorticosteroids: current and future directionsBr J Pharmacol20111631294321198556
   PubMed Web of Science ®Google Scholar
• GibsonPGSimpsonJLThe overlap syndrome of asthma and COPD: what are its features and how important is it?Thorax200964872873519638566
   PubMed Web of Science ®Google Scholar
• JamiesonDBMatsuiECBelliAEffects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013188218719223668455
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• GershonACroxfordRCalzavaraACardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary diseaseJAMA Intern Med2013173131175118523689820
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med2013152453324461613
   PubMed Web of Science ®Google Scholar
• CowanDCCowanJOPalmayREffects of steroid therapy on inflammatory cell subtypes in asthmaThorax201065538439019996343
   PubMed Web of Science ®Google Scholar
• HananiaNACraterGDMorrisANBenefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPDRespir Med201210619110122040533
   PubMed Web of Science ®Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of ‘triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax20086359259818245142
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200918074175019644045
   PubMed Web of Science ®Google Scholar
• SahaSBrightlingCEEosinophilic airway inflammation in COPDInt J Chron Obstruct Pulmon Dis200611394718046901
   PubMedGoogle Scholar